Brighter AB (publ) announced that it has received ethical approval for the research pilot in the United Arab Emirates. The approval is granted by the country's Ministry of Health and Prevention's (MoHAP) research ethics committee. The approval marks the last local requirement that was needed to start the pilot.

What remains now is to finalize the training of the healthcare providers, and then start onboarding patients. In addition to the ethical approval, the UAE Ministry of Health has also granted Brighter import-clearance approval. Pilot projects of this kind are essential for Brighter in order to confirm the benefits that Actiste brings to people with diabetes in a local setting.

The UAE study is a high-level pilot project that the company hopes will confirm the fit of Actiste in the local setting, and pave the way for a subsequent roll out to more patients on a commercial basis.